Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD ‐1 and VEGF , in Chinese Patients With Advanced Solid Tumors
Cancer Medicine · 2025-03 · 14 (6)
DOI: 10.1002/cam4.70653 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Medicine, online erschienen am 20.03.2025. Verfasst von Fenghua Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cancer Prevention Center, Sun Yat-Sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Neoplasms, Programmed Cell Death 1 Receptor, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Akeso Biopharma, Inc..
Abstract (Originalsprache)
Background
Ivonescimab (AK112) is a first‐in‐class bispecific antibody that simultaneously targets programmed death‐1 (PD‐1) and vascular endothelial growth factor (VEGF) with cooperative binding. We report the safety, pharmacokinetics (PK), and pharmacodynamics (PD) profiles of ivonescimab in patients suffered from advanced solid tumors.
Methods
A multicenter, open‐label, dose‐escalation, phase I study was conducted in five hospitals in China. Ivonescimab was used as a monotherapy. The dose of ivonescimab intravenously administered was 3, 5, 10, 20, and 30 mg/kg every 2 weeks (Q2W), and 10 and 20 mg/kg every 3 weeks (Q3W). Safety, PK, and PD of ivonescimab were evaluated.
Results
A total of 59 patients treated in the study. Only one dose‐limiting toxicity (DLT) occurred in 1 out of 9 patients in the 10 mg/kg Q2W cohort, indicating that no maximum tolerated dose was reached. Among the participants, 53 patients (89.8%) experienced treatment‐related adverse events (TRAEs), with the most common being proteinuria (33.9%), aspartate aminotransferase elevation (27.1%), white blood cell count decrease (22.0%), alanine aminotransferase elevation (20.3%), and anemia (20.3%). Fourteen patients (23.7%) had ≥ Grade 3 TRAEs, and 7 patients (11.9%) experienced serious TRAEs. Notably, there were no reported deaths associated with the TRAEs, and no dose‐dependent increase in adverse events was observed. The half‐life of ivonescimab ranged from 5.0 to 7.3 days following single‐dose administration across all dose levels. The serum concentrations of ivonescimab increased with escalating doses in an approximately dose‐proportional manner. Following multiple doses, the accumulation ratio ranged from 1.1 to 1.7, suggesting mild accumulation of ivonescimab. The steady state was achieved after 5 doses. Ivonescimab occupancy on PD‐1 sustained over 80% across the treatment period. Serum VEGF level was rapidly down‐regulated after each administration.
Conclusions
In patients with advanced solid tumors, ivonescimab monotherapy was well‐tolerated and demonstrated a linear PK characteristics. PD profiles showed the promising potential of ivonescimab for the management of advanced solid tumors. Trial Registration: ClinicalTrials.gov (NCT04597541)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Cancer Prevention Center, Sun Yat-Sen University, Guangzhou, Guangdong, China.
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.
- Department of Gynecology, Hunan Cancer Hospital, Changsha, Hunan, China.
- Department of Hepatobiliary Pancreatic Gastric Medicine, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, China.
- The Department of Head and Neck Radiation, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, China.
- Department of Medical Oncology, Henan Cancer Hospital, Zhengzhou, Henan, China.
ORCID-Profile: Huiyan Luo, Xufang Yu, Ruihua Xu
Förderung
- Akeso Biopharma, Inc.
Zitieren
APA
Wang, F., Wei, X., Zheng, Y., Wang, J., Ying, J., Chen, X., Luo, S., Luo, H., Yu, X., Chen, B., Ma, L., & Xu, R. (2025). Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD ‐1 and VEGF , in Chinese Patients With Advanced Solid Tumors. Cancer Medicine, 14(6). https://doi.org/10.1002/cam4.70653
Vancouver
Wang F, Wei X, Zheng Y, Wang J, Ying J, Chen X, et al. Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD ‐1 and VEGF , in Chinese Patients With Advanced Solid Tumors. Cancer Medicine. 2025;14(6). doi:10.1002/cam4.70653
BibTeX
@article{Wang2025,
author = {Wang, Fenghua and Wei, Xiaoli and Zheng, Yulong and Wang, Jing and Ying, Jieer and Chen, Xiaozhong and Luo, Suxia and Luo, Huiyan and Yu, Xufang and Chen, Benchao and Ma, Lei and Xu, Ruihua},
title = {Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD ‐1 and VEGF , in Chinese Patients With Advanced Solid Tumors},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {6},
doi = {10.1002/cam4.70653}
}
EUVIMED